This company has been acquired
IHLX.F Stock Overview
A clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Incannex Healthcare Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.038 |
| 52 Week High | AU$0.10 |
| 52 Week Low | AU$0.038 |
| Beta | 2.09 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| IHLX.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.6% | -2.4% |
| 1Y | n/a | 7.8% | 23.3% |
Return vs Industry: Insufficient data to determine how IHLX.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how IHLX.F performed against the US Market.
Price Volatility
| IHLX.F volatility | |
|---|---|
| IHLX.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IHLX.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IHLX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Joel Latham | www.incannex.com |
Incannex Healthcare Limited, a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.
Incannex Healthcare Inc. Fundamentals Summary
| IHLX.F fundamental statistics | |
|---|---|
| Market cap | US$43.03m |
| Earnings (TTM) | -US$13.21m |
| Revenue (TTM) | US$670.51k |
64.2x
P/S Ratio-3.3x
P/E RatioIs IHLX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IHLX.F income statement (TTM) | |
|---|---|
| Revenue | AU$1.01m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.01m |
| Other Expenses | AU$20.99m |
| Earnings | -AU$19.98m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,970.61% |
| Debt/Equity Ratio | 0% |
How did IHLX.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/30 06:30 |
| End of Day Share Price | 2023/11/16 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2023/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Incannex Healthcare Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arron Aatkar | Edison Investment Research |
| David Joseph Storms | Stonegate Capital Partners, Inc. |